EUVIMEDEUVIMED entdecken
Vergleichsstudie

Effectiveness of the quercetin use in patients with COVID-19 with concomitant type 2 diabetes mellitus

Zoriana Tylishchak, Oleksandra Pryshliak, Oleksandr Boichuk, Sergiy Fedorov, Andrii Protsyk, Taras Kobryn, Ruslan Miziuk

Wiadomości Lekarskie · 2024

DOI: 10.36740/wlek/191875 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Wiadomości Lekarskie, 2024. Verfasst von Zoriana Tylishchak und 6 weiteren Autor:innen. Beteiligte Einrichtung: IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE. Hauptthemen laut MEDLINE: Quercetin, Diabetes Mellitus, Type 2, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To conduct a comparative analysis of the effectiveness of basic therapy and basic therapy with the inclusion of quercetin in patients with COVID-19 with concomitant type 2 diabetes. Material and methods There were examined 60 patients with COVID-19 with concomitant T2DM. Upon admission into the hospital and again after 10 days, serum levels of interleukin-6, C-reactive protein, procalcitonin, ferritin, endothelin-1 were determined, and capillaroscopy of the nail plate was performed. Patients of the group I (30) against the background of protocol therapy received 0.5 g of quercetin intravenously once a day for 10 days. Patients of the group II (30) received to basic therapy.

Results

After the treatment in patients of the group I general weakness decreased, body temperature normalized, improved saturation indicators, the level of acute-phase parameters (interleukin-6, CRP and ferritin) significantly decreased, a positive effect of quercetin on the level of D-dimer in blood serum was noted, indices of pericapillary edema and hemosiderin deposition significantly decreased, indices diameter of the arterial part of the capillary and capillary network density significantly increased.

Conclusions

The use of quercetin against the background of basic therapy in patients with COVID-19 and concomitant T2DM reliably reduces the level of acute-phase indices, has an important clinical significance for reducing endothelial dysfunction and for preventing thrombotic complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuercetinDiabetes Mellitus, Type 2COVID-19HumansMaleFemaleMiddle AgedSARS-CoV-2COVID-19 Drug TreatmentC-Reactive ProteinFerritinsAgedInterleukin-6Treatment OutcomeAntioxidants

Stichwörter der Autor:innen

respiratory insufficiencyD-dimercapillaroscopyendothelin

Substanzen

QuercetinC-Reactive ProteinFerritinsInterleukin-6Antioxidants

Autor:innen und Institutionen

  • IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE.

Zitieren

APA

Tylishchak, Z., Pryshliak, O., Boichuk, O., Fedorov, S., Protsyk, A., Kobryn, T., & Miziuk, R. (2024). Effectiveness of the quercetin use in patients with COVID-19 with concomitant type 2 diabetes mellitus. Wiadomości Lekarskie. https://doi.org/10.36740/wlek/191875

Vancouver

Tylishchak Z, Pryshliak O, Boichuk O, Fedorov S, Protsyk A, Kobryn T, et al. Effectiveness of the quercetin use in patients with COVID-19 with concomitant type 2 diabetes mellitus. Wiadomości Lekarskie. 2024. doi:10.36740/wlek/191875

BibTeX
@article{Tylishchak2024,
  author = {Tylishchak, Zoriana and Pryshliak, Oleksandra and Boichuk, Oleksandr and Fedorov, Sergiy and Protsyk, Andrii and Kobryn, Taras and Miziuk, Ruslan},
  title = {Effectiveness of the quercetin use in patients with COVID-19 with concomitant type 2 diabetes mellitus},
  journal = {Wiadomości Lekarskie},
  year = {2024},
  doi = {10.36740/wlek/191875}
}
Kostenlos starten →